In today's world, Manidipine is a topic that arouses great interest and debate in different areas of society. Its relevance and diversity of approaches has led to extensive discussion and reflection on its implications. From academic perspectives to the everyday environment, Manidipine has generated endless questions and positions that seek to understand its scope and impact on our reality. In this article, we will delve into a detailed analysis of Manidipine, exploring its different aspects and offering a comprehensive vision to understand its importance and current challenges.
Clinical data | |
---|---|
Trade names | Manyper, Caldine, etc. |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C35H38N4O6 |
Molar mass | 610.711 g·mol−1 |
3D model (JSmol) | |
| |
|
Manidipine is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.
It was patented in 1982 and approved for medical use in 1990.
The alkylation between N-(2-hydroxyethyl)piperazine (1) and Benzhydryl Bromide (2) gives 2-(4-benzhydrylpiperazin-1-yl)ethanol (3). The reaction with Diketene (4) gives 2-(4-benzhydryl-1-piperazinyl)ethyl acetoacetate (5). The reaction with 3-nitrobenzaldehyde (6) and Methyl 3-aminocrotonate (7) completed the synthesis of Manidipine (8).